Resultados: 4

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: To carry out a cost-effectiveness and budget impact analysis of antipsychotic use in adults to treat schizophrenia from the perspective of the Unified Health System (SUS). Methods: A Markov model simulated the treatment of schizophrenic patients with an initial average age of 25 years and a li...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 9 (2), 2017

Objective: The aim of this study is to conduct a systematic review on cost-effectiveness analysis of oral antipsychotic agents to identify the trend of cost-effectiveness of drugs available for the treatment of schizophrenia. Methods: A search was conducted in three databases (MEDLINE, LILACS and PsycINF...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 8 (3), 2017

Objectives: The aim of this study was to describe the socio-demographic and clinical variables, identify the determinants of length of stay and estimate the cost of inpatient treatment of schizophrenia in Minas Gerais, Brazil. Methods: A non-concurrent cohort was conducted in three psychiatric hospitals ...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 8 (3), 2017

Objectives: To conduct a cost-effectiveness analysis of second-generation antipsychotics (SGA) for schizophrenia in Brazil. Methods: A Markov model was built for the evaluation of the cost-effectiveness of risperidone, quetiapine, ziprasidone and olanzapine in the Brazilian public health system. The time...

Texto completo (link principal)     Texto completo (link alternativo)